Levitex image2

 

 

 

Levitex Foams Ltd

Levitex Foams was founded in 2016 after identifying a need in the global market for quality therapeutic mattresses. The Company’s new foam products directly address poor body alignment and posture whilst a patient is in bed. Failure to address poor posture can significantly exacerbate a patient’s condition, leading to issues such as pressure sores and possible sleep deprivation. The result of which can worsen the patient’s condition, often leading to lengthy and therefore more costly stays in hospital.

The newly developed foam has far reaching possibilities to aid individuals with complex neurological illness or injury, including Multiple Sclerosis, Cerebral Palsy, Motor Neurone Disease, stroke, and hypoxic brain injury. The Company reports that there are a number of vertical markets that would benefit from the products they offer. These include but are not limited to the NHS, care homes, retail, sports, automotive and aerospace. To date, the company have been in discussions with a number of organisations within these markets whilst continuing to gather evidence through clinical trials to enable seamless traction.Levitex foam image

 

The estimated annual cost of pressure ulcer care in the UK was between £1.4 bn and £2.1 bn a year.  In the United States, the Centers for Medicare and Medicaid Services report that pressure ulcers are one of the eight preventable iatrogenic illnesses. If a pressure ulcer is acquired in the hospital the hospital will no longer receive reimbursement for the person’s care.


The Company sees a real opportunity globally to re-think standard hospital / care home type mattresses. By using the very latest foam material combined with the very latest scientific research, they can cement their brand into a market that is not only stable but is growing and is actively seeking solutions to what is an increasingly costly problem.


Aside from the clinical and health markets there remains the huge domestic retail and consumer markets that are seeking a high quality, but affordable product that has superior properties to those already on the market. The company is in talks with a number of on-line, high street retailers and partner organisations to establish channels to market. 

 

www.Levitex.co.uk

ProductEIS
SectorTherapeutics
Aim of fundingCommercialisation
HMRC Advanced Assurance receivedYes
Envisaged investor exitMinimum 4-5 years
Targeted return170p for every 100p